Doctors hail new era for cancer screening as major research shows effectiveness of Galleri test
Doctors
have told health services to prepare for a new era of cancer screening
after a study found a simple blood test could spot multiple cancer types
in patients before they develop clear symptoms.
The Pathfinder study
offered the blood test to more than 6,600 adults aged 50 and over, and
detected dozens of new cases of disease. Many cancers were at an early
stage and nearly three-quarters were forms not routinely screened for.
It is the first time results from the Galleri test, which looks for cancer DNA in the blood, have been returned to patients and their doctors, to guide cancer investigations and any necessary treatment.
The Galleri test has been described as a potential “gamechanger” by NHS England, which is due to report results from a major trial
involving 165,000 people next year. Doctors hope the test will save
lives by detecting cancer early enough for surgery and treatment to be
more effective, but the technology is still in development.
“I
think what’s exciting about this new paradigm and concept is that many
of these were cancers for which we do not have any standard screening,”
Dr Deb Schrag, a senior researcher on the study at the Memorial Sloan
Kettering Cancer Center in New York, told the European Society for Medical Oncology meeting in Paris on Sunday.
In
the Pathfinder study, 6,621 adults aged 50 and over were offered the
Galleri blood test. For 6,529 volunteers, the test was negative, but it
flagged a potential cancer in 92.
Further tests
confirmed solid tumours or blood cancer in 35 people, or 1.4% of the
study group. The test spotted two cancers in a woman who had breast and
endometrial tumours.
Beyond spotting the
presence of disease, the test predicts where the cancer is, allowing
doctors to fast-track the follow-up work needed to locate and confirm a
cancer. “The signal of origin was very helpful in directing the type of
work-up,” said Schrag. “When the blood test was positive, it typically
took under three months to get the work-ups completed.”
The
test identified 19 solid tumours in tissues such as the breast, liver,
lung and colon, but it also spotted ovarian and pancreatic cancers,
which are typically detected at a late stage and have poor survival rates.
The
remaining cases were blood cancers. Out of the 36 cancers detected in
total, 14 were early stage and 26 were forms of the disease not
routinely screened for.
Further analyses found
the blood test was negative for 99.1% of those who were cancer-free,
meaning only a small proportion of healthy people wrongly received a
positive result. About 38% of those who had a positive test turned out
to have cancer. Schrag said that the test not yet ready for population-wide screening and that people must continue with standard cancer screening
while the technology is improved. “But this still suggests a glimpse of
what the future may hold with a really very different approach to
cancer screening,” she said.
Fabrice
André, the director of research at Gustave Roussy cancer centre in
Villejuif, France, said: “Within the next five years, we will need more
doctors, surgeons and nurses, together with more diagnostic and
treatment infrastructure, to care for the rising number of people who
will be identified by multi-cancer early detection tests.”
Naser
Turabi, the director of evidence and implementation at Cancer Research
UK, said: “Blood tests for multiple types of cancer used to belong in
the realm of science fiction, but now they are an area of cancer
research that is showing promise for patients.
“Research
like this is crucial for making progress against late-stage cancers and
giving more patients the chance of a good outcome. The Pathfinder trial
results give us a better understanding of how frequently cancer is
found by this blood test in people who haven’t been previously
diagnosed.
“But we will need data from larger
studies to fully assess this test and other similar tests in
development, especially to understand whether people actually survive
for longer after their cancer is picked up.”
|